Al- Anbar Medical Journal

[1] X.-W. Xuet al.Clinical findings in a group of patients
infected with the 2019 novel coronavirus (sars-cov-2) out-
side of wuhan, china: retrospective case series.bmj, 368,
2020.
[2] . Tanget al.On the origin and continuing evolution of
sars-cov-2.Natl. Sci. Rev., 2020.
[3] A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T.
McGuire, and D. Veesler. Structure, function, and anti-
genicity of the sars-cov-2 spike glycoprotein.Cell, 2020.
[4] C.-C. Lai, T.-P. Shih, W.-C. Ko, H.-J. Tang, and P.-R.
Hsueh.Severe acute respiratory syndrome coronavirus
2 (sars-cov-2) and corona virus disease-2019 (covid-19):
the epidemic and the challenges.Int. J. Antimicrob.
Agents, page 105924, 2020.
[5] J. F. W. Chan, S. K. P. Lau, K. K. W. To, V. C. C.
Cheng, P. C. Y. Woo, and K.-Y. Yuen.Middle east
respiratory syndrome coronavirus: another zoonotic be-
tacoronavirus causing sars-like disease.Clin. Microbiol.
Rev., 28(2):465–522, 2015.
[6] Q. Wu T. Zhang and Z. Zhang. Probable pangolin ori-
gin of sars-cov-2 associated with the covid-19 outbreak.
Curr. Biol., 2020.
[7] K.G.Andersen,A.Rambaut,W.I.Lipkin,E.C.
Holmes, and R. F. Garry.The proximal origin of sars-
cov-2.Nat. Med., 26(4):450–452, 2020.
[8] Y.-R. Guoet al.The origin, transmission and clini-
cal therapies on coronavirus disease 2019 (covid-19) out-
breakan update on the status.Mil. Med. Res., 7(1):1–10,
2020.
[9] Y. A. Helmy, M. Fawzy, A. Elaswad, A. Sobieh, S. P.
Kenney, and A. A. Shehata. The covid-19 pandemic: A
comprehensive review of taxonomy, genetics, epidemiol-
ogy, diagnosis, treatment, and control.J. Clin. Med.,
9(4):1225, 2020.
[10] V. K. Goyal and C. Sharma. The novel coronavirus 2019:
A naturally occurring disaster or a biological weapon
against humanity:A critical review of tracing the ori-
gin of novel coronavirus 2019.
[11] L. McNamara.Covid-19fighting fear and the coron-
avirus pandemic with precautions and quality supple-
ments.medRxiv.
[12] T. Phan.Genetic diversity and evolution of sars-cov-2.
Infect. Genet. Evol., 81:104260, 2020.
[13] P. Forster, L. Forster, C. Renfrew, and M. Forster. Phy-
logenetic network analysis of sars-cov-2 genomes.Proc.
Natl. Acad. Sci., 117(17):9241–9243, 2020.
[14] S. F. Ahmed, A. A. Quadeer, and M. R. McKay.
[15] T. T. Leet al.The covid-19 vaccine development land-
scape.Nat Rev Drug Discov, 19:305–306, 2020.
[16] S. Wu. Progress and concept for covid19 vaccine devel-
opment.Biotechnol. J., page 2000147, 2020.
[17] M. Uddinet al.Sars-cov-2/covid-19:Viral genomics,
epidemiology,vaccines,and therapeutic interventions.
Viruses, 12(5):526, 2000.
[18] R. Lane. Sarah gilbert: carving a path towards a covid-
19 vaccine.Lancet (London, England), 395(10232):1247,
2020.
[19] Q. Gaoet al.Rapid development of an inactivated vac-
cine for sars-cov-2.bioRxiv, 2020.
[20] D. Ricks.Race for a coronavirus vaccine:Thanks in
part to institutional support, cansino biologics, moderna
therapeutics, and other developers are exploring diverse
approaches against sars-cov-2.Genet. Eng. Biotechnol.
News, 40(5):16–18, 2020.
[21] N. Zhanget al.Current development of covid-19 diagnos-
tics, vaccines and therapeutics.Microbes Infect., 2020.
[22] A. Sarkar and U. Maulik. Vaccines and treatment strate-
gies for sars-cov-2. 2020.
[23] W.-H. Chen, U. Strych, P. J. Hotez, and M. E. Bottazzi.
The sars-cov-2 vaccine pipeline: an overview.Curr. Trop.
Med. reports, pages 1–4, 2020